Vktx stock price investors monitoring vktx stock price

Investors monitoring vktx stock price are noting a 14-day RSI reading just above 65, indicating a near-overbought condition yet backed by strong fundamental catalysts. Analysts expect quarterly earnings to potentially accelerate share price momentum if R&D milestones are achieved. Let's take a closer look to see what the different types of shareholders can tell us about Viking Therapeutics. Previously we covered a bullish thesis on Viking Therapeutics, Inc. (VKTX) by Kontra Investments in February 2025, which highlighted the obesity epidemic, the $100 billion market potential, and VK2735’s differentiated safety and dual formulation strategy. The company’s stock price has depreciated approximately 10.77% since our coverage as the thesis has not yet played out. Remarkable-Ad5326 shares a similar view but emphasizes valuation, short interest, and buyout potential. In comparative valuation models, vktx stock price trades at a price-to-book multiple higher than sector average, reflecting premium growth expectations tied to its proprietary therapy pipeline.